Tumocin Injection, Vial

Although the exact mechanism of action of bleomycin sulfate is unknown, available evidence indicates that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis.

Tumocin is known to cause single, and to a lesser extent, double-stranded breaks in DNA. In in vitro and in vivo experiments, bleomycin has been shown to cause cell cycle arrest in G2 and in mitosis. When administered into the pleural cavity in the treatment of malignant pleural effusion, bleomycin sulfate acts as a sclerosing agent.


Tumocin is used for Malignant effusions, Lymphoma, Squamous cell or testicular tumours

Tumocin is also used to associated treatment for these conditions: Cervical Cancers, Head and Neck Carcinoma, Intracranial Germ Cell Tumors, Lymphoma, Hodgkins, Malignant Pleural Effusions, Non-Hodgkin's Lymphoma (NHL), Ovarian Cancer, Penile Cancer, Pneumothorax, Testicular Cancer, Vulvar Cancers, Early Kaposi's sarcoma


Trade Name Tumocin
Generic Bleomycin
Bleomycin Other Names Bleocin, Bleomicin, Bleomicina, Bleomycin, Bleomycine, Bleomycinum
Type Injection, Vial
Formula C55H84N17O21S3
Weight Average: 1415.552
Monoisotopic: 1414.518979905
Protein binding


Therapeutic Class Cytotoxic Chemotherapy
Manufacturer Neon Laboratories, Neon Lab
Available Country India, Philippines
Last Updated: June 23, 2021 at 9:09 am


Bleomycin Structure


Tumocin dosage

Squamous cell carcinoma

  • Over 80 years: 15 mg per week (in a single or divided doses), total 100 mg
  • 70-79 years: 30 mg/week, total 150-200 mg
  • 60-69 years: 30-60 mg/week, total 200-300 mg
  • Under 60 years: 30-60 mg/wk, total 500 mg. All to be applied through slow intravenous or intravenous infusion.

Malignant lymphomas: 15 mg once or twice a week to a total dose of 225 mg.

CrCl 20-40 mcg/ml: Admin 50% of normal dose.

IM/SC: Add 1-5 mL or 2-10 mL of sterile water for inj, NaCl 0.9% inj, or bacteriostatic water for inj to the vial labelled as containing 15 IU or 30 IU of bleomycin, respectively, to provide a soln containing 3-15 IU/mL. 

IV: Add 5 mL or 10 mL of NaCl 0.9% into the vial labelled as containing 15 IU or 30 IU of bleomycin, respectively, to provide a soln containing ≤3 IU/mL. Admin slowly over a 10-min period. Intrapleural: Dissolve 60 IU of bleomycin in 50-100 mL NaCl 0.9% inj.

Side Effects

Common side effects of Tumocin Sulfate include injection site reactions (pain, redness, warmth, itching, or swelling), fever, chills, vomiting, loss of appetite, weight loss, darkening or discoloration of the skin, changes in fingernails or toenails, itching, or pain near your tumor.


Caution should be taken in patient with severe heart disease, Renal impairment, Elderly & Pregnancy.


Increased incidence and severity of lung toxicity with previous or concurrent radiotherapy to the chest. Combination with vinca alkaloids may result to a syndrome corresponding to morbus Raynaud, ischaemia which can lead to necrosis of peripheral parts of the body (fingers, toes, nose tip). May reduce the absorption of phenytoin. Increased risk of agranulocytosis with clozapine.

Food Interaction

No interactions found.

Half Life

115 minutes

Pregnancy & Breastfeeding use

Pregnancy Category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk.


Acute pulmonary infection or greatly reduced lung function. Concomitant brentuximab, cisplatin or oxygen. Lactation.

Acute Overdose

Symptoms: Hypotension, fever, rapid pulse and general symptoms of shock. 

Management: Symptomatic. In case of resp complications, treat with a corticosteroid and a broad-spectrum antibiotic.

Storage Condition

Store between 2-8°C. Protect from light.

Innovators Monograph

Tumocin contains Bleomycin see full prescribing information from innovator // generic/bleomycin/bleomycin-sulfate-prescribing-information" Monograph